1Y Target$212.06Near-term target
5Y Target$345.11Compound horizon
10Y Target$898.02Long-dated conviction
FCF$575mTTM · 03/26C+FCF $575m — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+32.7%TTM YoYARevenue +32.7% — hypergrowth, top decile
D/E0.20A-D/E 0.20 — conservative leverage, strong balance sheet
P/S3.7xBP/S 3.7x — in line with software/tech peers
PEG1.13B+PEG 1.13 — near fair value, classic Lynch benchmark (1.0)
Why now
Specialty Chemicals · market cap $20.2b. Down 22% from 52-week high of $221.00 — deep drawdown territory. Revenue growing +33% — in hypergrowth territory. 22 sell-side analysts rate this a Buy with a mean 1-yr target of $212.06 (implying +24% upside).
Moat
Speculative bucket — the moat thesis is forward-looking; without proven margin structure or capital efficiency yet, the durability argument is about IP / network effects / first-mover position that the company hasn't fully monetized.
Risk
Currently unprofitable (margin -4.2%) — path to GAAP profitability is the core thesis risk. ROE -2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Horizon
1-3 yr $212.06 (22-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $345.11 — requires the platform / technology to reach commercial scale. 10 yr $898.02 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.